Newcelx Ltd stock is traded at $2.89, with a volume of 38,619. It is up +12.89% in the last 24 hours and down -2.39% over the past month. NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Previous Close:
$2.56
Open:
$2.30
24h Volume:
38,619
Relative Volume:
0.95
Market Cap:
$16.69M
Revenue:
-
Net Income/Loss:
-$2.17M
P/E Ratio:
-
EPS:
-$17.34
Net Cash Flow:
-$4.82M
1W Performance:
+13.33%
1M Performance:
-2.39%
6M Performance:
-12.95%
1Y Performance:
-30.36%
1-Day Range:
$0.00$0.00
1-Week Range:
$2.28$2.92
52-Week Range:
$1.83$5.62
Newcelx Ltd Stock (NCEL) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS